Closing in on Anal Cancer: Has the Era of Immune Checkpoint Inhibitors Truly Arrived?

Squamous cell carcinoma of the anus (SCCA) is a rare malignancy, with rising incidence and mortality largely attributed to human papillomavirus (HPV) infection. While chemoradiotherapy remains the standard treatment for locoregional disease, the management of recurrent or metastatic SCCA has long been a challenge due to limited therapeutic options and poor prognosis. Recent advancements, particularly the use of immune checkpoint inhibitors (ICIs), have revolutionized the treatment landscape. It has been demonstrated that combining carboplatin-paclitaxel with immunotherapy improves progression-free survival (PFS) and overall survival (OS) in metastatic SCCA, representing a practice-changing development. HPV-positive tumors, with their distinct immunogenic profile, have shown promise in responding to ICIs, although the risk of increased toxicity remains. Current research continues to explore novel treatment combinations, including ICIs, targeted therapies, and chemoradiotherapy, to enhance treatment outcomes and overcome resistance mechanisms. As ICIs gain a more central role in the treatment of SCCA, ongoing trials and future studies will define the optimal strategies for improving patient outcomes in both early and advanced disease.